Between July @ , @ , and March @ , @ ( when enrolment was prematurely terminated ) , @ patients received initial bevacizumab and docetaxel ; @ ( @ % ) were randomly assigned ( @ to bevacizumab and capecitabine versus @ to bevacizumab only ) .